Poly medicure ltd

This company which was establised in 1995 has come a long way and could prove to an excellent bet itn the future. The company is engaged in the manufacture of following products used for medical purposes.
Infusion therapy products
I.V.cannulae
Three way stop cock
Three way stop cock HP
Stop cock with extention tube
I.V. infusion sets
Flow regulator
Obturator
Extension tubes high and low pressure
Polyvol Borette set
Anaesthesia products
Suction cateters
Nasal oxygen cannula
Oxygen catheter
Yankaur suction set
Guedel airway
Urology products
Urine collection bags
Urine drainage catheters
Gastronetrology products
Ryle's tube
Levin's tube
Mucus extractor
Infact feeding tube
Umbilical catheter
stomach tube
Blood management products
Blood administration set
Blood bag systems
transfer bag
Blood taking set
Surgery and wound drainage products
redon drain
Close wound suction unit
thoracic drainage catheter
Thoracic catheter with trocar
abdominal drainage set
Water sealed drainage set

POLYMED's Quality System encompasses a comprehensive and exhaustive series of physical, chemical, biological & microbiological tests and inspection at different stages in the manufacturing cycle, begining with constant surveillance of raw materials and its suppliers; intensive in-process control of all manufactured components & sub-assemblies to the final inspection & testing of the finished products. POLYMED has successfully implemented a well documented QMS (Quality Management System) which has been accredited by SGS Yarsley International Certification Services, United Kingdom with ISO 9001:2000, ISO-13485:2003 and CE mark from DNV, Norway thus making the entire product range compliant with International Quality Standards.
The company reported a turnover of Rs 213 million for the quarter ending dec 07 and a net profit of 22.2 million on an equity base of 55.06 million reslting in to a quarterly eps of rs 3.82 The company paid a dividend of 25% for the last financial year and one can expect a better one this year. The plant in china is expected to begin production in the first quarter of the current financial which will further add to topline and bottomline of the company. The stock is avaiable at a p/e of around 7 and is a very good long term bet.